|
|
|
|
| LEADER |
03965nam a2200337 u 4500 |
| 001 |
EB000943839 |
| 003 |
EBX01000000000000000737429 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Wells, George A.
|
| 245 |
0 |
0 |
|a Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation
|h Elektronische Ressource
|c authors, George Wells [and 9 others]
|
| 246 |
3 |
1 |
|a New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c April 9, 2012, 2012
|
| 300 |
|
|
|a 1 PDF file (v, 173, ii, 13 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Stroke / prevention & control
|
| 653 |
|
|
|a Atrial Fibrillation / economics
|
| 653 |
|
|
|a Anticoagulants / therapeutic use
|
| 653 |
|
|
|a Atrial Fibrillation / complications
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Therapeutic review
|
| 500 |
|
|
|a Title from PDF title page. - Accompanied with: Anticoagulation monitoring and reversal strategies for Dabigatran, Rivaroxaban, and Apixaban : a review of clinical effectiveness / prepared by Canadian Agency for Drugs and Technologies in Health
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK169793
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a These NOACs include the direct thrombin inhibitor, dabigatran, and the direct factor Xa inhibitors, rivaroxaban and apixaban, which have either been approved (dabigatran and rivaroxaban) for use or are currently under regulatory review (apixaban) for the prevention of stroke and systemic embolism (SE) in patients with AF. Although NOACs have demonstrated efficacy within clinical trials in preventing stroke and SE in patients with AF, the relative effectiveness and cost-effectiveness in clinical practice of these agents is not clear. In addition, the relative effectiveness and cost-effectiveness of the NOACs and warfarin within specific subpopulations of AF patients is not clear. Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. Are there sub-populations of AF patients that would benefit more from using NOACs compared to warfarin?2.
|
| 520 |
|
|
|a Are there sub-populations of AF patients that would benefit more from one of the NOACs versus another? At the time of this report, apixaban was not approved by Health Canada for the prevention of stroke and SE in patients with non-valvular AF. Therefore, while the science reports included apixaban in addition to rivaroxaban and dabigatran, the recommendations presented in this report apply at present only to the two NOACs that are approved for this indication in Canada, namely dabigatran and rivaroxaban
|
| 520 |
|
|
|a Atrial fibrillation (AF), the most common cardiac rhythm abnormality, is associated with substantial morbidity. AF-related mortality is mainly attributable to complications of stroke. Stroke risk can be quantified using a validated tool such as the CHADS2 score. Warfarin, a vitamin K antagonist, is the standard of care for patients with AF and has demonstrated efficacy in the prevention of stroke. Warfarin has a narrow therapeutic window, produces varied responses among patients, and interacts with some types of food and other drugs, all of which necessitates routine laboratory monitoring. Improved understanding of the blood clotting cascade has led to the development of several new oral anticoagulants (NOACs) that offer a more targeted mechanism of anticoagulation.
|